US 9,808,521 B2
Silicon dioxide nanoparticles and the use thereof for vaccination
Markus Weigandt, Mannheim (DE); Andrea Hanefeld, Heidelberg (DE); Armin Kuebelbeck, Bensheim (DE); and Gregor Larbig, Gelnhausen (DE)
Assigned to MERCK PATENT GMBH, Darmstadt (DE)
Filed by Merck Patent GmbH, Darmstadt (DE)
Filed on Jun. 30, 2016, as Appl. No. 15/197,870.
Application 15/197,870 is a division of application No. 14/611,891, filed on Feb. 2, 2015, granted, now 9,433,673.
Application 14/611,891 is a division of application No. 13/054,169, granted, now 8,980,324, previously published as PCT/EP2009/005078, filed on Jul. 13, 2009.
Claims priority of application No. 10 2008 033 175 (DE), filed on Jul. 15, 2008.
Prior Publication US 2016/0303228 A1, Oct. 20, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 47/48 (2006.01); B82Y 5/00 (2011.01); A61K 9/10 (2006.01); A61K 9/14 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 9/143 (2013.01); A61K 9/5115 (2013.01); A61K 39/0005 (2013.01); A61K 47/48015 (2013.01); A61K 47/48023 (2013.01); A61K 47/48284 (2013.01); A61K 47/48861 (2013.01); B82Y 5/00 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/62 (2013.01); Y10T 428/2982 (2015.01)] 19 Claims
 
1. A nanoparticle having a diameter of 5 to 50 nm suitable for parenteral administration, comprising
a) a silicon dioxide matrix, and
b) a surface functionality to which an antigen to be targeted at antigen-presenting cells is attached,
with the proviso that neither said surface functionality nor said antigen is a major histocompatibility (MHC) molecule.